ImpediMed Limited, a medical technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. The company offers SOZO, a noninvasive BIS device for the assessment of lymphedema, and deliver snapshot of fluid status and tissue composition; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. It sells its devices to hospitals and clinics. The company was incorporated in 1999 and is headquartered in Pinkenba, Australia.
Stock data | 2023 | Change |
---|---|---|
Price | $0.032480714575720666 | N/A |
Market Cap | $58.48M | N/A |
Shares Outstanding | 1.80B | 7.23% |
Employees | 76.00 | N/A |
Shareholder Equity | 60.88M | 19.27% |
Valuation | 2023 | Change |
---|---|---|
P/S Ratio | 7.68 | N/A |
P/B Ratio | 0.96 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -0.2281 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $7.61M | N/A |
Earnings | -$13.89M | N/A |
Gross Margin | 0.8626 | N/A |
Operating Margin | -2.04 | N/A |
Net income margin | -1.82 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $46.51M | N/A |
Total Debt | $979.16K | N/A |
Cash on Hand | $30.93M | N/A |
Debt to Equity | 0.0873 | -13.94% |
Cash to Debt | $31.59 | N/A |
Current Ratio | $8.88 | 37.88% |